Sarepta rallies as Piper upbeat on eteplirsen NDA

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

Sarepta Therapeutics (SRPT +4.9%) is on the move, and with today's gains the shares are up some 10% since Wednesday when disappointing dystrophin production data from Prosensa's (RNA) drisapersen boosted sentiment around eteplirsen.

Today's catalyst appears to be a note out of Piper which emphasizes eteplirsen's safety profile.

SRPT is now up more than 50% since the end of August.